Publication

The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.

Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM
J Pharmacol Exp Ther. 2012 340 (2): 404-21

PMID: 22088953 · PMCID: PMC3263969 · DOI:10.1124/jpet.111.187443

MeSH Terms (37)

3,4-Dihydroxyphenylacetic Acid Adenosine A2 Receptor Antagonists Animals Brain Calcium Signaling Catalepsy Corpus Striatum Disease Models, Animal Dose-Response Relationship, Drug Drug Synergism Drug Therapy, Combination Glutamic Acid G Protein-Coupled Inwardly-Rectifying Potassium Channels Haloperidol HEK293 Cells Humans Levodopa Male Monoamine Oxidase Motor Neuron Disease Oxidopamine Parkinson Disease Picolinic Acids Protein Binding Psychomotor Performance Pyrimidines Rats Rats, Sprague-Dawley Rats, Wistar Reaction Time Receptors, G-Protein-Coupled Receptors, Metabotropic Glutamate Substantia Nigra Thallium Transfection Triazoles Tyrosine 3-Monooxygenase

Connections (3)

This publication is referenced by other Labnodes entities:

Links